- Home
- RFL vs VTVT Comparison
RFL vs VTVT Comparison
Compare RFL & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFL
- VTVT
- Stock Information
- Founded
- RFL 2017
- VTVT 2015
- Country
- RFL United States
- VTVT United States
- Employees
- RFL N/A
- VTVT N/A
- Industry
- RFL Real Estate
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- RFL Finance
- VTVT Health Care
- Exchange
- RFL Nasdaq
- VTVT Nasdaq
- Market Cap
- RFL 54.4M
- VTVT 54.4M
- IPO Year
- RFL N/A
- VTVT 2015
- Fundamental
- Price
- RFL $1.34
- VTVT $20.89
- Analyst Decision
- RFL
- VTVT Strong Buy
- Analyst Count
- RFL 0
- VTVT 2
- Target Price
- RFL N/A
- VTVT $35.50
- AVG Volume (30 Days)
- RFL 77.7K
- VTVT 4.2K
- Earning Date
- RFL 12-10-2025
- VTVT 11-12-2025
- Dividend Yield
- RFL N/A
- VTVT N/A
- EPS Growth
- RFL N/A
- VTVT N/A
- EPS
- RFL N/A
- VTVT N/A
- Revenue
- RFL $732,000.00
- VTVT $17,000.00
- Revenue This Year
- RFL N/A
- VTVT N/A
- Revenue Next Year
- RFL N/A
- VTVT N/A
- P/E Ratio
- RFL N/A
- VTVT N/A
- Revenue Growth
- RFL 35.56
- VTVT N/A
- 52 Week Low
- RFL $1.28
- VTVT $12.62
- 52 Week High
- RFL $3.19
- VTVT $26.99
- Technical
- Relative Strength Index (RSI)
- RFL 45.24
- VTVT 48.86
- Support Level
- RFL $1.32
- VTVT $20.19
- Resistance Level
- RFL $1.44
- VTVT $21.20
- Average True Range (ATR)
- RFL 0.07
- VTVT 0.97
- MACD
- RFL 0.01
- VTVT -0.30
- Stochastic Oscillator
- RFL 28.57
- VTVT 33.54
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin, being investigated for the treatment of type 1 diabetes (T1D). Its product pipeline includes TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.